Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07496918 · ClinicalTrials.gov registry record · Phase 2
Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)
A Phase 2 study, sponsored by Massachusetts Institute of Technology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT07496918: Recruiting Phase 2 study, sponsored by Massachusetts Institute of Technology.
NCT07496918 is a Phase 2 study that is actively recruiting participants, run by Massachusetts Institute of Technology. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07496918, a Phase 2 study, is actively recruiting participants, sponsored by Massachusetts Institute of Technology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.
Primary Outcome
Using Electroencephalogram (EEG), investigators will determine whether GENUS will affect brain oscillations, including those in the gamma band.
Interventions
- DEVICE GENUS
- DEVICE Tactile GENUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
What NCT07496918 shows while recruiting
NCT07496918 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which GENUS is the first listed.
NCT07496918 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07496918 about?
NCT07496918 is a clinical study titled "Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)". Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slo...
What is the current status of trial NCT07496918?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2018-02-20. Estimated completion is 2027-01-30.
What interventions are being tested in trial NCT07496918?
The interventions under investigation include: GENUS (DEVICE), Tactile GENUS (DEVICE).
Who is sponsoring clinical trial NCT07496918?
This trial is sponsored by Massachusetts Institute of Technology, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07496918's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI